Furthermore, a line of anti-ICAM-1 antibody-based chimeric antigen receptor T cells was shown to exhibit significant antitumor effects both in vitro and in vivo in preclinical models of gastric cancer and thyroid cancer, suggesting they are applicable to the treatment of hematological malignancies, including MM [33,43,44]. The gene discussed is ICAM1; the disease is Miyoshi myopathy.